Prognostic value of changes in vibration‐controlled transient elastography parameters for liver, cardiovascular and mortality outcomes in individuals with type 2 diabetes and metabolic dysfunction‐associated steatotic liver disease: The Rio de Janeiro type 2 diabetes cohort
Authors' conclusion
VCTE parameters changes, LSM increase and CAP reduction, provide prognostic information for adverse liver, cardiovascular, and mortality outcomes in individuals with T2D and MASLD.
Study context
- Population
- Patients with T2D and MASLD (Rio de Janeiro T2D cohort) with 2 vibration-controlled transient elastography (VCTE) exams at least 2 years apart
- Participants
- 288 patients
- Exposure
- Changes in VCTE parameters between 2 exams ≥2 years apart
- Outcome
- Any liver-related events (LREs), cardiovascular events (CVEs) and all-cause mortality
- Follow-up
- Median 6 years
Methodological detailsmultivariable Cox analyses adjusted for liver and cardiometabolic factors
- Multivariable Cox analyses adjusted for liver and cardiometabolic factors
Main finding
As reported in the abstract
LREs, CVEs and all-cause mortality by VCTE parameter changes
- Events: Liver-related events (LREs)
- 22
- Events: Cardiovascular events (CVEs)
- 28
- Events: all-cause deaths
- 37
- LREs: baseline liver stiffness measurement (LSM) strongest predictor; LSM increase added prognostic value, HR (1-SD increment)
- 1.5 [1.0-2.1]
- CVEs: LSM increase, HR
- 1.7 [1.3-2.3]
- CVEs: Controlled attenuation parameter (CAP) reduction, HR (1-SD decrease)
- 1.5 [1.0-2.3]
Observational data: associations, not effects.
Further findings
Subgroups by LSM and CAP changes
- Increased LSM and reduced CAP: highest risk for CVEs, HR
- 5.3 [1.4-19.6]
- Increased LSM and reduced CAP: highest risk for all-cause mortality, HR
- 3.4 [1.2-9.6]
- Increased LSM without CAP reduction: highest risk for LREs, HR
- 3.5 [0.9-12.9]
Original publication
Prognostic value of changes in vibration‐controlled transient elastography parameters for liver, cardiovascular and mortality outcomes in individuals with type 2 diabetes and metabolic dysfunction‐associated steatotic liver disease: The Rio de Janeiro type 2 diabetes cohort. Diabetes Obes Metab. Published 16 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →